

## **CURRICULUM VITAE**

Maria G. Tektonidou, MD, PhD

Work address: [REDACTED]  
[REDACTED].

Phone (office): [REDACTED], mobile: [REDACTED], Fax: [REDACTED]

E-mail address: [REDACTED]

### **Current position**

- Associate Professor in Rheumatology, Medical School, National and Kapodistrian University of Athens, Greece
- Head of Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Athens, Greece
- Deputy Chair of the Center of Rare Connective tissue diseases, Laiko University Hospital, Athens, Greece

### **Degrees**

- 1985-1991 Medical degree MD, School of Medicine, Demokriteion University, Greece
- 2001 PhD Thesis, Department of Pathophysiology, Medical School, University of Athens, Greece

### **Postgraduate Training and Fellowship Appointments:**

- Feb 1991-Jan 1993: Medical service in rural/remote area (Draviskos, Serres, Greece)
- Feb 1993-April 1995 Resident in Internal Medicine, General Hospital of Serres, Greece
- May 1995-Aug 1995: Medical coordinator in a humanitarian mission with 'Medecins du Monde' in Ajerbaijan
- 1995-2000 Resident in Rheumatology, Department of Pathophysiology, School of Medicine, University of Athens (Director: prof. H.Moutsopoulos)

### **Faculty Appointment**

- 2000-2001: Senior Research Fellow, Department of Pathophysiology, School of Medicine, University of Athens
- 2001-present: Consultant Rheumatologist in Onasis Cardiac Surgery Center

- 2001-2007: Consultant Rheumatologist, Euroclinic Hospital, Athens, Greece
- 2007-May 2010 Director Rheumatologist, Euroclinic Hospital, Athens, Greece
- June-Sept 2009: Guest Researcher, National Institutes of Health (NIH), Clinical Sciences section, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, MD (Senior Investigator Dr Michael Ward).
- June 2010: Lecturer Rheumatologist, Head of Rheumatology Unit, First Department of Internal Medicine, Laiko Hospital, School of Medicine, University of Athens, Greece
- 2010-present: Head of the Systemic lupus erythematosus outpatient clinic
- 2010-present: Head of the Antiphospholipid syndrome outpatient clinic
- Jan 2013: Assistant Professor of Rheumatology, Head of Rheumatology Unit, First Department of Internal Medicine, Laiko Hospital, School of Medicine, University of Athens, Greece
- Oct 2015: Head of Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Laiko Hospital, School of Medicine, University of Athens, Greece
- Sept 2016-present: Associate Professor of Rheumatology, First Department of Propaedeutic Internal Medicine, Laiko Hospital, School of Medicine, University of Athens, Greece
- 2019-present: 1-2 monthly visits per year at the NIAMS/NIH, Bethesda, USA as Guest Researcher working on outcome measures in systemic autoimmune diseases, especially systemic lupus erythematosus

### **Board Certificate**

- 1991: License to practice medicine
- 2000: Greek Board of Rheumatology, Diplomate National Rheumatology Board Examination, Athens, Greece

### **Teaching activities-Educational responsibilities**

- Rheumatic Diseases (4th and 6<sup>th</sup> year Med. Students)
- History Taking & Physical Examination (4th year Med. Students)
- Differential diagnosis (4th and 6th year Med students)
- Physical Examination of the Rheumatic disease patient (4th and 6th year Med students)
- Connective tissue disorders (4<sup>th</sup> year Dentistry students)
- Systemic autoimmune diseases (Rheumatology and Internal Medicine Residents)

- Head of the educational program for the residents in Rheumatology in the First Propaedeutic and Internal Medicine Department, University of Athens (2016-present)
- Co-Head of the inter-university academic educational program for the residents in Rheumatology (2014 - present)
- Member of the steering committee (and contribution by several lectures and as a master's thesis supervisor) of the Postgraduate studies program in Rheumatology of the Medical School, National University of Athens (2017-present)
- Participation with lectures and as a master's thesis supervisor in three postgraduate studies programs of the Medical School, National University of Athens: 1. Thrombophilia and Hemostasis (lectures/master thesis supervision: antiphospholipid syndrome) 2. Diabetes mellitus (lecture: Musculoskeletal manifestations in diabetes mellitus) 3. Cardiovascular and renal diseases (lecture: Cardiovascular risk in Systemic Lupus erythematosus and in Antiphospholipid syndrome")
- Member of the organizing committee and participation with lectures in Postgraduate Lessons in Rheumatology /under the auspices of the Greek Rheumatology Society (2005-present)
- Chapters in 4 educational books edited by the Medical School, National and Kapodistrian University of Athens

### **Professional Societies**

- 1995 Athens Medical Association
- 2000 Member of the Hellenic Society for Rheumatology

### **Member of National Committees**

- 2012-2014: Member of the national committee for the approval of off-label drugs, "National Drug Organization", Greece
- 2016-present: National representative in the "EULAR epidemiology and health services research (ESCEHSR) Standing Committee"
- 2018: Vice president of the "National Committee for the assessment and reimbursement of medicines", Ministry of Health, Greece

### **Member of scientific or organizing committee of medical congresses**

- 22<sup>nd</sup> Panhellenic Rheumatology Congress, Athens, December 2010.

- ‘The scientific basis of Rheumatology. A primer for clinicians’. Athens, September 10-12, 2010.
- 15th International Congress on Antiphospholipid Antibodies (APLA)-LACA, Rio de Janeiro, Brazil, September 2013
- 9th European Meeting in SLE, Athens, Greece, April 2014
- 24th Panhellenic Rheumatology Congress, December 2018, Athens, Greece
- 15th International Congress on Antiphospholipid Antibodies, 21-24 September 2016, Cyprus
- 10th European Lupus Meeting, 5-8 October 2016, Venice, Italy
- 4th International Congress on Controversies in Rheumatology and Autoimmunity, CORA 2017, March 8-11, Bologna, Italy
- 11th European Lupus Meeting, 21-24 March 2018, Dusseldorf, Germany
- 26th Panhellenic Rheumatology Congress, 6-9 December 2018, Athens, Greece
- 5th International Congress on Controversies in Rheumatology & Autoimmunity, CORA 2019, March 14-16, Florence, Italy
- 16th International Congress on Antiphospholipid Antibodies, September 17-20, 2019, Manchester, UK
- 12th European Lupus Meeting, March 25-28, 2020, Bruges, Belgium
- Co-chair, 12<sup>th</sup> International Congress on Autoimmunity 2020, Athens, Greece, 20-24 May 2020

### **Member of Study groups and Research networks**

- Member of the European Forum on Antiphospholipid Antibodies (2004-present)
- Member of the Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (2004-present)
- Member of the European League against Rheumatism (EULAR) study group on SLE (2010-present)
- Member of the Steering Committee of the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking ('APS ACTION') (2013-2014)
- Member of the European Vasculitis Study Group (2014-present)
- Member of the International Lupus Nephritis Trials Network (2012-present)
- Member of the Executive Committee of the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking ('APS ACTION') (2016-present)
- Member as an expert of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN-ReCONNECT) in 2 groups: a. Systemic Lupus Erythematosus and b. Antiphospholipid Syndrome (2018-present)

- Member of the Executive Committee of the ‘European Lupus Society’- SLEuro (2018-2020)
- Member of the INTEGRATE project (co-funded by the European Union’s Health Programme (2014-2020) for “INTEGRATING patient reported outcomes, clinical data and quality indicators to physician drive data in clinical management of chronic rheumatic diseases: the paradigm of Systemic Lupus Erythematosus” (2019)
- Leader of the ERN-ReCONNET endorsed project “SURvey of cardiovascular Risk Factor in Systemic Lupus Erythematosus and in Antiphospholipid syndrome” (2019-present)
- Leader of the EULAR Antiphospholipid Syndrome (APS) Study Group (2019-present)

### **Member of Task Force groups for the development of Recommendations and Classification criteria**

- Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (13th International Congress on antiphospholipid antibodies)
- Task Force on the prevention and management of thrombosis in Antiphospholipid Antibody-positive patients (13th International Congress on antiphospholipid antibodies)
- Task force on “Antiphospholipid syndrome treatment trends: 14th International Congress on Antiphospholipid Antibodies”
- Task Force on “Antiphospholipid Syndrome Treatment Trends Report: 15th International Congress on Antiphospholipid Antibodies”
- EULAR Recommendations for the management of Systemic lupus erythematosus with neuropsychiatric Manifestations
- Joint EULAR/ERA-EDTA recommendations for the management of adult and paediatric lupus nephritis
- EULAR recommendations on Women Health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with in Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome’
- EULAR recommendations for the management of Antiphospholipid syndrome in adults (Convenor)
- Member of the international group (and co-author) for the development of “EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus”
- EULAR Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases including Systemic Lupus Erythematosus and antiphospholipid syndrome (Convenor) (ongoing)
- Member of the steering committee for the “New Antiphospholipid Syndrome Classification Criteria Development”

## **Primary investigator (PI), sub-Investigator (SubI) (or participant) in European/International projects and sponsored trials**

- Participant in the RCT “Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)” (2001-2007)
- Participant in projects based on the Catastrophic antiphospholipid syndrome Registry (European Forum on Antiphospholipid antibodies) (2002-)
- Participant in MAINTAIN Nephritis Trial and other projects of the MAINTAIN Nephritis Trial Group (2004-2016)
- PI, subI or participant in several projects of the APS ACTION International Clinical Database and Repository (“Registry”) (2011-)
- Member of the steering committee/SubI of the Phase III RCT “Efficacy of hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis-free patients with no other systemic autoimmune disease” (2013-2015)
- Participant in pharma-sponsored phase III and IV clinical trials in systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and in one phase II trial in SLE

## **Research Grants**

- PI: “Aseptic necrosis of the femoral heads in patients with antiphospholipid syndrome” (Greek Society of Rheumatology, 2001)
- PI: Type I Interferon- and autophagy-related gene expression in primary antiphospholipid Syndrome and systemic lupus erythematosus (Novartis 2018).
- PI: Carotid and femoral atherosclerosis in patients with Systemic Lupus Erythematosus syndrome in comparison with healthy controls and patients with diabetes mellitus and rheumatoid arthritis (Pfizer 2013)
- PI: “Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk vs Rheumatoid Arthritis” (Greek Society of Rheumatology, 2013)
- PI: Subclinical atherosclerosis in antiphospholipid syndrome versus healthy controls and diabetes mellitus (Pfizer 2014).
- PI: Development of a national registry for primary and systemic lupus-associated antiphospholipid syndrome (Greek Society of Rheumatology, 2015)
- PI: “RNA sequencing in peripheral blood monocytes in patients with antiphospholipid syndrome” (Pfizer 2016).
- PI: “Stress Perfusion Cardiac Magnetic Resonance [CMR] in patients with primary and systemic lupus erythematosus-associated antiphospholipid syndrome” (Greek Society of Rheumatology, 2017-8)

- Convenor: EULAR Recommendations for the management of adult Antiphospholipid syndrome (2017-2019)
- Convenor: EULAR Recommendations for cardiovascular risk management in Rheumatic and Musculoskeletal Diseases including Systemic lupus erythematosus and antiphospholipid syndrome (2018-20)

### **Invited speaker**

in several national, European and international scientific meetings and conferences, including the International Congress on Antiphospholipid Antibodies (2004-present), EULAR (2011, 2018, 2019, 2020), Lupus Academy (2012), European Lupus meetings (2014-present), ERA/EDTA Congress (2015), EULAR Scientifically Endorsed Course on Systemic Lupus Erythematosus (2015-present), CORA meetings (2015-present), International Congress on Autoimmunity (2016-present)

### **Member of Editorial Boards**

- Hellenic Rheumatology Journal (2012-)
- Lupus Journal (2014-)
- Mediterranean Journal of Rheumatology (2015-)

### **Ad hoc Reviewer**

*(chronological order)* Lupus Journal, Rheumatology (Oxford), The Journal of Rheumatology, Annals of Rheumatic Diseases, Scandinavian Journal of Rheumatology, Clinical Physiology, Acta Pharmacologica Sinica, Journal of Autoimmunity, Arthritis Care and Research, Saudi Med Journal, Journal of Clinical Rheumatology, Expert Opinion on Pharmacotherapy, Arthritis Rheumatology, European Journal of Pain, International Journal Rheumatology, Nature Reviews Nephrology, Dermatology, PLoS ONE, Mediterranean Journal of Rheumatology, Journal of Autoimmunity and Research, Am Journal Nephrology, Nature Reviews Rheumatology, Lupus Science and Medicine, Clinical Studies and Medical Case Reports, Clinical Medicine and Research, Scientific Reports, Current Medical Research & Opinion, The Open Rheumatology Journal, Diabetology & Metabolic Syndrome, Nature Reviews Nephrology, Advances in Chronic Kidney Disease, Expert Review of Clinical Immunology, Frontiers in Immunology, European Journal of Clinical Investigation, Therapeutic Advances in Musculoskeletal Disease, Advances in Chronic Kidney Disease, The Lancet

### **Abstract Reviewer in European and International congresses**

- European Congress of Rheumatology “EULAR 2011” (Abstract Reviewer in the topics of SLE, Sjogren’s syndrome and APS)
- EULAR 2013 (Abstract Reviewer in the topics of SLE, Sjogren’s syndrome and APS)
- EULAR 2015 (Abstract Reviewer in the topics of SLE, Sjogren’s syndrome and APS)

- EULAR 2016 (Abstract Reviewer in the topics of SLE, Sjogren's syndrome and APS)
- EULAR 2017 (Abstract Reviewer in the topics of SLE, Sjogren's syndrome and APS)
- International congress on SLE, Buenos Aires, Argentina, April 2013
- APLA-LACA congress, Rio de Janeiro, Brazil, September 2013
- 9th European Meeting in SLE, Athens, Greece, April 2014
- 15th International Congress on Antiphospholipid Antibodies, 21-24 September 2016, Cyprus
- 10th European Lupus Meeting, 5-8 October 2016, Venice, Italy
- 4th International Congress on Controversies in Rheumatology & Autoimmunity, CORA 2017, March 8-11, Bologna, Italy
- 11th European Lupus Meeting, 21-24 March 2018, Dusseldorf, Germany
- 11th International Congress on Autoimmunity, 16-20 May 2018, Lisbon, Portugal
- 5th International Congress on Controversies in Rheumatology & Autoimmunity, CORA 2019, March 14-16, Florence, Italy
- 16th International Congress on Antiphospholipid Antibodies, September 17-20, 2019, Manchester, UK
- 12th European Lupus Meeting, 25-27 March 2020, Bruges, Belgium

#### **Research Grant Reviewer**

- ESCMID research grants (2013-)
- Dutch Arthritis Foundation (DAF, Reumafonds) (2016-)

#### **Book reviewer**

- Review after invitation by Elsevier of the book proposal for a publication titled 'Antiphospholipid Syndrome in Systemic Autoimmune Diseases, 2nd edition (edited by R. Cervera, G. Espinosa, M. Khamashta) (February 25, 2015)

#### **PUBLICATIONS**

- 120 published articles in peer-reviewed international journals (pubmed) and 3 accepted for publication, 4 submitted
- Citations: 5159 (Scopus)/ 7941 (Google Scholar)
- h-index: 35 (Scopus), 38 (Google Scholar)

#### **Chapters in books:**



- M.G Tektonidou. Antiphospholipid syndrome. Orphanet encyclopedia. November 2001-update May 2004. <http://www.orpha.net./data/patho/GB/uk-APS.pdf>
- M.G Tektonidou, H.M Moutsopoulos. Osteoarticular manifestations of antiphospholipid syndrome. In “Hughes Syndrome-Antiphospholipid syndrome”. M.A Khamashta (Editor), second edition, Springer-Verlag, London, 2006.
- Ruiz-Irastorza G, Pengo V, Tektonidou MG, Ruiz-Arruza I, Cuadrado M, Khamashta M. In “Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies”. Doruk Erkan, Silvia S. Pierangeli (Editors), Springer, April 2012.
- Tektonidou MG, Adrogué H, Vaidya S. In “Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies”. Doruk Erkan, Silvia S. Pierangeli (Editors), Springer, April 2012.
- Bournia L. Tektonidou M. Infections and Autoimmune Renal Diseases. In ‘Infection and Autoimmunity 2nd Edition, 2015 (edited by Rose, Shoenfeld & Agmon-Levin)
- Danieli Andrade, Ricard Cervera, Hannah Cohen, Mark Crowther, Maria J. Cuadrado, Guillaume Canaud, David A. Garcia, Maria Gerosa, Thomas L. Ortel, Vittorio Pengo, Anisur Rahman, Jane E. Salmon, Rohan Willis, Scott C. Woller, Doruk Erkan, Michael D. Lockshin, and Maria G. Tektonidou. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report, 2017: 317-338. In “Antiphospholipid Syndrome”. Springer International Publishing AG, Erkan, MD. Lockshin (editors).
- Mark Crowther, Kimberly J. Legault, David A. Garcia, Maria G. Tektonidou, Amaia Ugarte, Ian N. Bruce, Doruk Erkan, and Guillermo Ruiz-Irastorza. Prevention and Treatment of Thrombotic Antiphospholipid Syndrome, 2017: 223-233. In “Antiphospholipid Syndrome”. Springer International Publishing AG, Erkan, M.D. Lockshin (editors).

### **Publications in international peer-reviewed journals (pubmed):**

1. Keramiotou K, Anagnostou C, Kataxaki E, Galanos A, Sfikakis PP, **Tektonidou MG**. The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial. *RMD Open*. 2020 Jan;6(1). pii: e001141.
2. Bournia VK, Kottas K, Panopoulos S, Konstantonis G, Iliopoulos A, **Tektonidou MG**, Tzioufas AG, Sfikakis PP, Vlachoyiannopoulos PG. Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. *Clin Exp Rheumatol*. 2020 Jan 14

3. **Tektonidou MG.** JAK inhibitors: promising for a wider spectrum of autoimmune diseases? *Lancet.* 2019 Dec 7;394(10214):2047-2048.
4. Chatzidionysiou K, Samoli E, Sfikakis PP, **Tektonidou MG.** Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. *Ann Rheum Dis.* 2020 Feb;79(2):304-307.
5. Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. *Rheumatology (Oxford).* 2019
6. Conti F, Andreoli L, Crisafulli F, Mancuso S, Truglia S, **Tektonidou MG.** Does seronegative obstetric APS exist? "pro" and "cons". *Autoimmun Rev.* 2019 Dec;18(12):102407
7. Flessa CM, Vlachiotis S, Nezos A, Andreakos E, Mavragani CP, **Tektonidou MG.** Independent association of low IFN $\lambda$ 1 gene expression and type I IFN score/IFN $\lambda$ 1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. *Clin Immunol.* 2019 Dec;209:108265.
8. Laskari K, Pentazos G, Pitsilka D, Raftakis J, Konstantonis G, Toutouzas K, Siores E, **Tektonidou M,** Sfikakis PP. Joint microwave radiometry for inflammatory arthritis assessment. *Rheumatology (Oxford).* 2019 Sep 5. pii: kez373.
9. Vlachogiannis NI, Gatsiou A, Silvestris DA, Stamatelopoulos K, **Tektonidou MG,** Gallo A, Sfikakis PP, Stellos K. Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. *J Autoimmun.* 2020 Jan;106:102329.
10. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, **Tektonidou MG,** Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol.* 2019 Sep;71(9):1400-1412.
11. Aringer M, Costenbader K et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis.* 2019 Sep;78(9):1151-1159.
12. Xourgia E, **Tektonidou MG.** Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. *J Autoimmun.* 2019 Nov;104:102311.
13. Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M,

- Tektonidou M**, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H; APS ACTION. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. *J Thromb Haemost.* 2019 Dec;17(12):2069-2080.
14. Mavrogeni SI, Markousis-Mavrogenis G, Karapanagiotou O, Toutouzas K, Argyriou P, Velitsista S, Kanoupakis G, Apostolou D, Hautemann D, Sfrikakis PP, **Tektonidou MG**. Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study. *Clin Med.* 2019 Jul 23;8(7). pii: E1084.
  15. **Tektonidou MG**, Dasgupta A, Ward MM. Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. *Rheumatology (Oxford).* 2019 Oct 1;58(10):1794-1801.
  16. Tountas C, Protogerou AD, Bournia VK, Panopoulos S, Konstantonis G, **Tektonidou MG**, Gournizakis A, Beldekos D, Sfrikakis PP. Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. *Clin Exp Rheumatol.* 2019 Jul-Aug;37 Suppl 119(4):57-62.
  17. **Tektonidou MG**, Andreoli L, Limper M, Tincani A, Ward MM. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. *RMD Open.* 2019 Apr 28;5(1):e000924.
  18. Panousis NI, Bertias GK, Ongen H, Gergianaki I, **Tektonidou MG**, Trachana M, Romano-Palumbo L, Bielser D, Howald C, Pamfil C, Fanouriakis A, Kosmara D, Repa A, Sidiropoulos P, Dermitzakis ET, Boumpas DT. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. *Ann Rheum Dis.* 2019 Jun 5. pii: annrheumdis-2018-214379.
  19. Tountas C, Protogerou AD, Bournia VK, Panopoulos S, Konstantonis G, **Tektonidou MG**, Gournizakis A, Beldekos D, Sfrikakis PP. Mechanics of early biventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. *Clin Exp Rheumatol.* 2019 Jun 4
  20. Radin M, Sciascia S, Erkan D, Pengo V, **Tektonidou MG**, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedraza R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. *Semin Arthritis Rheum.* 2019 May 2. pii: S0049-0172(19)30090-3.
  21. **Tektonidou MG**, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. *Ann Rheum Dis.* 2019 May 15. pii: annrheumdis-2019-215213.

22. Sakkas LI, Bogdanos DP, Boumpas D, Mamouris Z, Gkoutzourelas A, Mavropoulos A, Tsouris Z, Liossis SN, Daoussis D, Vasilopoulos D, **Tektonidou M**, Tzioufas A, Efthymiou G, Dardiotis E, Kitas G, Sharif K, Blank M, Karussis D, Rimar D, Slobodin G, Porat-Katz BS, Vadasz Z, Amital H, Toubi E, Shoenfeld Y. The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. *Isr Med Assoc J*. 2019 Apr;21(4):292-297.
23. Palli E, Kravvariti E, **Tektonidou MG**. Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. *Front Immunol*. 2019 Mar 15;10:487.
24. Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, **Tektonidou MG**, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. *Thromb Res*. 2019 Mar;175:32-36
25. Tamirou F, Arnaud L, Talarico R, Scirè CA, Alexander T, Amoura Z, Avcin T, Bortoluzzi A, Cervera R, Conti F, Cornet A, Devilliers H, Doria A, Frassi M, Fredi M, Govoni M, Houssiau F, Lladò A, Macieira C, Martin T, Massaro L, Moraes-Fontes MF, Pamfil C, Paolino S, Tani C, Tas SW, **Tektonidou M**, Tincani A, Van Vollenhoven RF, Bombardieri S, Burmester G, Eurico FJ, Galetti I, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Costedoat-Chalumeau. Systemic lupus erythematosus: state of the art on clinical practice guidelines. *RMD Open*. 2018 Nov 27;4(2):e000793
26. Panopoulos S, **Tektonidou M**, Drosos AA, Liossis SN, Dimitroulas T, Garyfallos A, Sakkas L, Boumpas D, Voulgari PV, Daoussis D, Thomas K, Georgiopoulos G, Vosvotekas G, Vassilopoulos D, Sfikakis PP. Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. *Arthritis Res Ther*. 2018 Dec 4;20(1):267
27. Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, **Tektonidou M**, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A. Antiphospholipid syndrome: state of the art on clinical practice guidelines. *RMD Open*. 2018 Oct 18;4(Suppl 1):e000785.
28. de Jesús GR, Sciascia S, Andrade D, Barbhuiya M, **Tektonidou M**, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, Fortin PR, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Nascimento IS, Rosa R, Erkan D, Levy RA; APS ACTION. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. *BJOG*. 2019 Apr;126(5):656-661
29. Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, **Tektonidou MG**, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM. Myositis autoantibody profiles and their clinical

- associations in Greek patients with inflammatory myopathies. *Clin Rheumatol*. 2019 Jan;38(1):125-132.
30. Kravvariti E, Konstantonis G, Sfikakis PP, **Tektonidou MG**. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. *Rheumatology (Oxford)*. 2018 Dec 1;57(12):2158-2166
  31. Panopoulos S, Bournia VK, Konstantonis G, Fragiadaki K, Sfikakis PP, **Tektonidou MG**. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. *Autoimmun Rev*. 2018 Aug;17(8):816-820.
  32. Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, **Tektonidou M**, Moutsopoulos HM, Mavragani CP. B-cell activating factor and related genetic variants in lupus related atherosclerosis. *J Autoimmun*. 2018 Aug;92:87-92
  33. **Tektonidou MG**. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. *Front Immunol*. 2018 May 31;9:1181.
  34. Rodríguez-Pintó I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R; CAPS Registry Project Group. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. *Rheumatology (Oxford)*. 2018 Apr 11.
  35. Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, **Tektonidou M**, Sidiropoulos P, Erden A, Sfikakis PP, Bertias G, Boumpas DT. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. *Semin Arthritis Rheum*. 2018 Dec;48(3):467-474.
  36. Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, **Tektonidou MG**. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. *Semin Arthritis Rheum*. 2017 Oct 23.
  37. Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuilvy S, **Tektonidou MG**; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. *Arthritis Care Res (Hoboken)*. 2019 Jan;71(1):134-141
  38. Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. *Blood Adv*. 2017 Nov 16;1(25):2320-2324.
  39. Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, Bounas A, **Tektonidou M**, Lliossis SC, Daoussis D, Plastiras S, Karabela G, Stavropoulos E, Katsifis G, Vartela V, Kolovou G. Cardiovascular magnetic

- resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. *Lupus*. 2018 Apr;27(4):564-571.
40. Sfikakis PP, Arida A, Panopoulos S, Fragiadaki K, Pentazos G, Laskari K, **Tektonidou M**, Markomichelakis N. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. *Arthritis Rheumatol*. 2017 Dec;69(12):2380-2385.
  41. **Tektonidou MG**, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. *Ann Rheum Dis*. 2017 Dec;76(12):2009-2016.
  42. Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, **Tektonidou MG**; APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. *Lupus*. 2018 Mar;27(3):399-406.
  43. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, Konstantonis G, Liossis SN, Manoussakis M, Sakkas L, **Tektonidou M**, Tzioufas AG, Vlachoyiannopoulos PG, Kani C, Paterakis P, Litsa P, Vassilopoulos D. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. *Clin Exp Rheumatol*. 2017 Mar 3.
  44. Sciascia S, Radin M, Yazdany J, **Tektonidou M**, Cecchi I, Roccatello D, Dall'Era M Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. *Rheumatol Int*. 2017 Mar 3. doi: 10.1007/s00296-017-3686-5
  45. **Tektonidou MG**, Ward MM. Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. *J Rheumatol*. 2017 Feb 15. pii: jrheum.160546. doi: 10.3899/jrheum.160546
  46. Mavrogeni S, Markousis-Mavrogenis G, Koutsogeorgopoulou L, Dimitroulas T, Bratis K, Kitas GD, Sfikakis P, **Tektonidou M**, Karabela G, Stavropoulos E, Katsifis G, Boki KA, Kitsiou A, Filaditaki V, Gialafos E, Plastiras S, Vartela V, Kolovou G. Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. *Int J Cardiol*. 2017 Feb 1. doi: 10.1016/j.ijcard.2017.01.104.
  47. **Tektonidou MG**, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid arthritis. *Autoimmun Rev*. 2017 Jan 29.
  48. Andreoli L, Bertias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojcono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, **Tektonidou M**, Yavuz S, Boumpas D, Tincani A. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. *Ann Rheum Dis*. 2016 Jul 25. pii: annrheumdis-2016-209770

49. **Tektonidou MG**, Wang Z, Ward MM. Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients with Systemic Lupus Erythematosus, 1996 To 2012. *Arthritis Rheumatol*. 2016 Jun 6. doi: 10.1002/art.3975
50. Andrade D, **Tektonidou MG**. Emerging Therapies in Antiphospholipid Syndrome. *Curr Rheumatol Rep*. 2016 Apr;18(4):22
51. **Tektonidou MG**, Dasgupta A, Ward MM. Risk of End-stage Renal Disease in Patients with Lupus Nephritis, 1970 to 2015 A systematic review and Bayesian meta-analysis. *Arthritis Rheumatol*. 2016 Jun;68(6):1432-41.
52. Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA; MAINTAIN Nephritis Trial Investigators. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. *Lupus Sci Med*. 2015 Nov 12;2(1):e000123.
53. Mavrogeni SI, Sfrikakis PP, Kitas GD, Kolovou G, **Tektonidou MG**. Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. *Semin Arthritis Rheum*. 2016 Apr;45(5):611-6
54. Tamirou F, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C, Ayala Gutierrez MD, Gilboe IM, **Tektonidou M**, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R, Houssiau FA; and the MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. *Ann Rheum Dis*. 2015 Mar
55. **Tektonidou MG**, Wang Z, Dasgupta A, Ward MM. Burden of serious infections in adults with systemic lupus erythematosus. A national population-based Study, 1996-2011. *Arthritis Care Res (Hoboken)*. 2015 Mar 2
56. Abreu MM, Danowski A, Wahl DG, Amigo MC, **Tektonidou M**, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. *Autoimmun Rev*. 2015 May;14(5):401-14
57. Arnaud L, Mathian A, Devilliers H, Ruffatti A, **Tektonidou M**, Forastiero R, Pengo V, Lambert M, Lefevre G, Martinez-Zamora MA, Balasch J, Wahl D, Amoura Z. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. *Autoimmun Rev*. 2015 Mar;14(3):192-200
58. Ntali S, Damjanov N, Drakakis P, Ionescu R, Kalinova D, Rashkov R, Malamitsi-Puchner A, Mantzaris G, Michala L, Pamfil C, Rednic S, **Tektonidou MG**, Tsiodras S, Vassilopoulos D, Vojinovic J, Bertias GK, Boumpas DT. Women's health and fertility, family planning and pregnancy in immune-mediated rheumatic diseases: a report from a south-eastern European Expert Meeting. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6):959-68

59. Georgiadou SP, Gamaletsou MN, Mpanaka I, Vlachou A, Goules AV, Ziogas DC, Syriou V, **Tektonidou MG**, Kaltsas G, Manoussakis MN, Sipsas NV. Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance. *Clin Infect Dis*. 2015 Mar 15;60(6):868-74
60. **Tektonidou MG**. Identification and treatment of APS renal involvement. *Lupus*. 2014 Oct;23(12):1276-8.
61. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, **Tektonidou MG**, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. *Autoimmun Rev*. 2014 Jun;13(6):685-96.
62. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, **Tektonidou M**, Espinosa G, Bertolaccini ML, Khamashta MA; Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). *Ann Rheum Dis*. 2014 Jan 24.
63. Arnaud L, Mathian A, Ruffatti A, Erkan D, **Tektonidou M**, Cervera R, Forastiero R, Pengo V, Lambert M, Martinez-Zamora MA, Balasch J, Zuily S, Wahl D, Amoura Z. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. *Autoimmun Rev*. 2014 Mar;13(3):281-91.
64. Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G; Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry". *Autoimmun Rev*. 2014 Feb;13(2):157-62.
65. Cuadrado MJ, Bertolaccini ML, Seed PT, **Tektonidou MG**, Aguirre A, Mico L, Gordon C, Ruiz-Irastorza G, Egurbide MV, Gil A, Espinosa G, Houssiau F, Rahman A, Martin H, McHugh N, Galindo M, Akil M, Amigo MC, Murru V, Khamashta MA. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). *Rheumatology (Oxford)*. 2014 Feb;53(2):275-84.
66. Kampolis C, **Tektonidou M**, Moysakakis I, Tzelepis GE, Moutsopoulos H, Vlachoyiannopoulos PG. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. *Semin Arthritis Rheum*. 2014 Feb;43(4):558-65.



67. Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. *Autoimmun Rev.* 2013 Sep;12(11):1085-90.
68. Konsta M, Bamias G, **Tektonidou MG**, Christopoulos P, Iliopoulos A, Sfrikakis PP. Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. *Rheumatology (Oxford).* 2013 Mar;52(3):448-51.
69. Bertias GK, **Tektonidou M**, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. *Ann Rheum Dis.* 2012 Nov;71(11):1771-82.
70. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. *Semin Arthritis Rheum.* 2013 Feb;42(4):417-23.
71. Ntziora F, Euthimiou A, **Tektonidou M**, Andreopoulos A, Konstantopoulos K. Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report. *J Med Case Rep.* 2011 Dec 4;5(1):563. doi: 10.1186/1752-1947-5-563.
72. Fragiadaki K, **Tektonidou MG**, Konsta M, Chrousos GP, Sfrikakis PP. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.. *J Rheumatol.* 2012 Jan;39(1):60-2.
73. **Tektonidou MG**. Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. *Int. J. Clin. Rheumatol.* 7 (2), 131–13 (2012).
74. Stoenoiu MS, Aydin S, **Tektonidou M**, Ravelingien I, le Guern V, Fiehn C, Remy P, Delahousse M, Petera P, Quémeneur T, Vasconcelos C, D'Cruz D, Gilboe IM, Jadoul M, Karras A, Depresseux G, Guillevin L, Cervera R, Cosyns JP, Houssiau FA; MAINTAIN Nephritis Trial Group. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. *Nephrol Dial Transplant.* 2012 May;27(5):1924-30.
75. **Tektonidou MG**, Ward MM. Validation of new biomarkers in systemic autoimmune diseases. *Nat Rev Rheumatol.* 2011 Nov 1;7(12):708-17.

76. **Tektonidou MG**, Dasgupta A, Ward MM. Suicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey. *Arthritis Care Res (Hoboken)*. 2011 Sep;63(9):1322-33.
77. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, **Tektonidou M**, Khamashta M Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.. *Lupus*. 2011 Feb;20(2):206-18.
78. Cervera R, **Tektonidou MG**, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. *Lupus*. 2011 Feb;20(2):174-81.
79. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, Vadya S, Adrogué HE, Solomon M, Zandman-Goddard G, Shoenfeld Y. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. *Lupus*. 2011 Feb;20(2):165-73.
80. **Tektonidou MG**. Presence of other autoimmune diseases in subjects with autoimmune thyroid disease. *Am J Med*. 2010 Oct;123(10):e23;
81. Louie GH, **Tektonidou MG**, Caban-Martinez AJ, Ward MM. Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey. *Arthritis Care Res (Hoboken)*. 2011 Feb;63(2):247-60
82. **Tektonidou MG**, Ward MM. Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. *Arthritis Res Ther*. 2010;12(5):R179.
83. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, **Tektonidou M**, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. *Ann Rheum Dis*. 2010 Dec;69(12):2083-9.
84. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassioulas I, **Tektonidou M**, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. *Ann Rheum Dis*. 2010 Dec;69(12):2074-82.

85. **Tektonidou MG.** MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. *Lupus.* 2010 Sep;19(10):1243-5.
86. Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. *Lupus.* 2010 Apr;19(4):412-8.
87. Caban-Martinez AJ, Louie GH, Ward MM, **Tektonidou MG.** Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked. *Arthritis Care Res (Hoboken).* 2010 Jan 15;62(1):140-1
88. Plastiras SC, Pamboucas CA, **Tektonidou M,** Toumanidis ST. Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. *Eur J Echocardiogr.* 2010 Mar;11(2):184-5.
89. Xynos ID, **Tektonidou MG,** Pikazis D, Sipsas NV. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. *Emerg Infect Dis.* 2009 Jun;15(6):956-9.
90. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, Shoenfeld Y, Ingelmo M, Espinos G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". *J Autoimmun.* 2009 May-Jun;32(3-4):240-5.
91. **Tektonidou MG,** Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Arthritis Rheum.* 2009 Jan 15;61(1):29-36.
92. **Tektonidou MG.** Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. *Clin Rev Allergy Immunol.* 2009 Jun;36(2-3):131-40
93. **Tektonidou MG,** Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. *J Rheumatol.* 2008 Oct;35(10):1983-8.
94. Serelis J, Kontogianni MD, Katsiogiannis S, Bletsas M, **Tektonidou MG,** Skopouli FN. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. *Clin Rheumatol.* 2008 Jun;27(6):795-7.
95. **Tektonidou MG,** Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? *Clin Rheumatol.* 2008 Apr;27(4):541-2.
96. Moyssakis I, **Tektonidou MG,** Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. *Am J Med.* 2007 Jul;120(7):636-42.

97. **Tektonidou MG.** Neurological complications of infliximab. *J Rheumatol.* 2007 Jan;34(1):237
98. **Tektonidou MG,** Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. *Arch Intern Med.* 2006 Nov 13;166(20):2278-84.
99. **Tektonidou MG.** Reiter's syndrome during intravesical BCG therapy for bladder carcinoma. *Clin Rheumatol.* 2007 Aug;26(8):1368-9.
100. **Tektonidou MG,** Moutsopoulos HM. Osteoarticular manifestations of antiphospholipid syndrome. *Rheum Dis Clin North Am.* 2006 Aug;32(3):523-35.
101. **Tektonidou MG,** Skopouli FN. Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis. *Clin Exp Rheumatol.* 2006 Mar-Apr;24(2 Suppl 41):S103.
102. **Tektonidou MG,** Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. *Clin Rheumatol.* 2007 Feb;26(2):258-60.
103. Serelis J, **Tektonidou MG,** Skopouli FN. A case with epilepsy, cognitive impairment, renal microangiopathy and high titres of anticentromere and anticardiolipin antibodies. *Lupus.* 2005;14(8):625-8.
104. **Tektonidou M.** Pulmonary hypertension. *N Engl J Med.* 2005 Jan 27;352(4):418-9
105. **Tektonidou MG,** Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. *Arthritis Rheum.* 2004 Aug;50(8):2569-79.
106. **Tektonidou MG,** Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos HM. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. *Ann Rheum Dis.* 2004 Sep;63(9):1159-61.
107. **Tektonidou MG,** Moutsopoulos HM. Immunologic factors in the pathogenesis of osteonecrosis. *Orthop Clin North Am.* 2004 Jul;35(3):259-63,
108. **Tektonidou MG,** Vlachoyiannopoulos PG. Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus.. *Lupus.* 2003;12(9):723-4.
109. **Tektonidou MG,** Skopouli FN. The successful use of i.v. gammaglobulin for Guillain-Barré syndrome following gold therapy in an RA patient. *Clin Exp Rheumatol.* 2003 May-Jun;21(3):404-5.
110. **Tektonidou MG,** Trakadas SI, Skopouli FN. Paravertebral leiomyosarcoma mimicking a chronic ongoing inflammatory process. *Clin Exp Rheumatol.* 2003 Mar-Apr;21(2):237-8.
111. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, **Tektonidou MG,** Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal

- women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. *Rheumatology (Oxford)*. 2003 May;42(5):645-51.
112. **Tektonidou MG**, Malagari K, Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HM. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. *Arthritis Rheum*. 2003 Mar;48(3):732-6.
113. Vlachoyiannopoulos PG, Kanellopoulos P, **Tektonidou M**, Moutsopoulos HM. Renal involvement in antiphospholipid syndrome. *Nephrol Dial Transplant*. 2001;16 Suppl 6:60-2. Review. No abstract available.
114. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, **Tektonidou MG**, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and nonrandomized studies. *JAMA*. 2001 Aug 15;286(7):821-30.
115. **Tektonidou MG**, Ioannidis JP, Moysakis I, Boki KA, Vassiliou V, Vlachoyiannopoulos PG, Kyriakidis MK, Moutsopoulos HM. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. *Ann Rheum Dis*. 2001 Jan;60(1):43-8.
116. **Tektonidou MG**, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. *QJM*. 2000 Aug;93(8):523-30.
117. **Tektonidou MG**, Petrovas CA, Ioannidis JP, Vlachoyiannopoulos PG, Moutsopoulos HM. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. *Eur J Clin Invest*. 2000 Jul;30(7):646-52.
118. Ioannidis JP, **Tektonidou MG**, Vlachoyiannopoulos PG, Stavropoulos-Giokas C, Spyropoulou-Vlachou M, Reveille JD, Arnett FC, Moutsopoulos HM. HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. *Hum Immunol*. 1999 Dec;60(12):1274-80.
119. **Tektonidou M**, Kaskani E, Skopouli FN, Moutsopoulos HM. Microvascular abnormalities in Sjögren's syndrome: nailfold capillaroscopy. *Rheumatology (Oxford)*. 1999 Sep;38(9):826-30.
120. Vlachoyiannopoulos PG, Petrovas C, **Tektonidou M**, Krilis S, Moutsopoulos HM. Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. *J Clin Immunol*. 1998 Nov;18(6):380-91.